Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1993 2
1994 2
1995 6
1996 2
1997 1
1998 3
1999 3
2000 4
2001 2
2002 3
2003 2
2004 4
2005 1
2007 1
2008 3
2009 2
2014 1
2015 2
2016 4
2017 6
2018 8
2019 5
2020 13
2021 20
2022 24
2023 17
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, García Deltoro M, Swindells S, Andrade-Villanueva JF, Wong A, Khuong-Josses MA, Van Solingen-Ristea R, van Eygen V, Crauwels H, Ford S, Talarico C, Benn P, Wang Y, Hudson KJ, Chounta V, Cutrell A, Patel P, Shaefer M, Margolis DA, Smith KY, Vanveggel S, Spreen W. Overton ET, et al. Among authors: talarico c. Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9. Lancet. 2021. PMID: 33308425 Clinical Trial.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, Latiff G, Pokrovsky V, Bredeek F, Smith G, Cahn P, Kim YS, Ford SL, Talarico CL, Patel P, Chounta V, Crauwels H, Parys W, Vanveggel S, Mrus J, Huang J, Harrington CM, Hudson KJ, Margolis DA, Smith KY, Williams PE, Spreen WR. Swindells S, et al. Among authors: talarico cl. N Engl J Med. 2020 Mar 19;382(12):1112-1123. doi: 10.1056/NEJMoa1904398. Epub 2020 Mar 4. N Engl J Med. 2020. PMID: 32130809 Clinical Trial.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
Cutrell AG, Schapiro JM, Perno CF, Kuritzkes DR, Quercia R, Patel P, Polli JW, Dorey D, Wang Y, Wu S, Van Eygen V, Crauwels H, Ford SL, Baker M, Talarico CL, Clair MS, Jeffrey J, White CT, Vanveggel S, Vandermeulen K, Margolis DA, Aboud M, Spreen WR, van Lunzen J. Cutrell AG, et al. Among authors: talarico cl. AIDS. 2021 Jul 15;35(9):1333-1342. doi: 10.1097/QAD.0000000000002883. AIDS. 2021. PMID: 33730748 Free PMC article.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Girard PM, Oka S, Andrade-Villanueva JF, Richmond GJ, Baumgarten A, Masiá M, Latiff G, Griffith S, Harrington CM, Hudson KJ, St Clair M, Talarico CL, Patel P, Cutrell A, Van Eygen V, D'Amico R, Mrus JM, Wu S, Ford SL, Chow K, Roberts J, Wills A, Walters N, Vanveggel S, Van Solingen-Ristea R, Crauwels H, Smith KY, Spreen WR, Margolis DA. Rizzardini G, et al. Among authors: talarico cl. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466. J Acquir Immune Defic Syndr. 2020. PMID: 33136751 Free PMC article. Clinical Trial.
Structure of human TRPM8 channel.
Palchevskyi S, Czarnocki-Cieciura M, Vistoli G, Gervasoni S, Nowak E, Beccari AR, Nowotny M, Talarico C. Palchevskyi S, et al. Among authors: talarico c. Commun Biol. 2023 Oct 19;6(1):1065. doi: 10.1038/s42003-023-05425-6. Commun Biol. 2023. PMID: 37857704 Free PMC article.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, Hermida AO, Thalme A, Belonosova E, Ajana F, Benn PD, Wang Y, Hudson KJ, Español CM, Ford SL, Crauwels H, Margolis DA, Talarico CL, Smith KY, van Eygen V, Van Solingen-Ristea R, Vanveggel S, Spreen WR. Jaeger H, et al. Among authors: talarico cl. Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11. Lancet HIV. 2021. PMID: 34648734 Clinical Trial.
A systematic literature review on the humanistic burden of cytomegalovirus.
Diaz-Decaro J, Myers E, Mucha J, Neumann M, Lewandowski W, Kaczanowska M, Schmidt E, Natenshon A, Talarico C, Buck PO. Diaz-Decaro J, et al. Among authors: talarico c. Curr Med Res Opin. 2023 May;39(5):739-750. doi: 10.1080/03007995.2023.2191477. Epub 2023 Apr 23. Curr Med Res Opin. 2023. PMID: 36938652 Review.
Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication.
Corona A, Madia VN, De Santis R, Manelfi C, Emmolo R, Ialongo D, Patacchini E, Messore A, Amatore D, Faggioni G, Artico M, Iaconis D, Talarico C, Di Santo R, Lista F, Costi R, Tramontano E. Corona A, et al. Among authors: talarico c. Antiviral Res. 2023 Sep;217:105697. doi: 10.1016/j.antiviral.2023.105697. Epub 2023 Aug 9. Antiviral Res. 2023. PMID: 37562607 Free article.
The SARS-CoV-2 spike protein binds and modulates estrogen receptors.
Solis O, Beccari AR, Iaconis D, Talarico C, Ruiz-Bedoya CA, Nwachukwu JC, Cimini A, Castelli V, Bertini R, Montopoli M, Cocetta V, Borocci S, Prandi IG, Flavahan K, Bahr M, Napiorkowski A, Chillemi G, Ooka M, Yang X, Zhang S, Xia M, Zheng W, Bonaventura J, Pomper MG, Hooper JE, Morales M, Rosenberg AZ, Nettles KW, Jain SK, Allegretti M, Michaelides M. Solis O, et al. Among authors: talarico c. Sci Adv. 2022 Dec 2;8(48):eadd4150. doi: 10.1126/sciadv.add4150. Epub 2022 Nov 30. Sci Adv. 2022. PMID: 36449624 Free PMC article.
136 results